SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
2.010
-0.090 (-4.29%)
At close: Sep 26, 2025, 4:00 PM EDT
2.140
+0.130 (6.47%)
After-hours: Sep 26, 2025, 7:46 PM EDT
Company Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders.
It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1.
SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
SAB Biotherapeutics, Inc.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Samuel Reich |
Contact Details
Address: 777 W 41st St. Miami Beach, Florida 33140 United States | |
| Phone | 605 679 6980 |
| Website | sabbiotherapeutics.com |
Stock Details
| Ticker Symbol | SABS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001833214 |
| CUSIP Number | 78397T103 |
| ISIN Number | US78397T2024 |
| Employer ID | 85-3899721 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Samuel J. Reich | Chief Executive Officer and Executive Chairman |
| Dr. Eddie Joe Sullivan Ph.D. | Co-Founder, President and Director |
| Christine E. Hamilton M.B.A. | Co-Founder and Independent Director |
| Lucy To | Executive Vice President and Chief Financial Officer |
| Dr. Christoph Bausch M.B.A., Ph.D. | Executive Vice President and Chief Operating Officer |
| Dr. Alexandra Kropotova M.B.A., M.D. | Executive Vice President and Chief Medical Officer |
| Dr. Edward D. Hamilton D.V.M. | Co-Founder and Board Observer |
| Kaelan Hollon J.D. | Vice President of Communications |
| Catherine DeRose | Vice President of Human Resources |
| Hua Wu Ph.D. | Senior Vice President of Product Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 26, 2025 | 8-K | Current Report |
| Sep 22, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Sep 2, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 29, 2025 | DEF 14A | Other definitive proxy statements |
| Aug 19, 2025 | PRE 14A | Other preliminary proxy statements |
| Aug 7, 2025 | 10-Q | Quarterly Report |
| Aug 5, 2025 | D | Notice of Exempt Offering of Securities |
| Jul 21, 2025 | 8-K | Current Report |
| Jul 17, 2025 | 8-K | Current Report |
| Jun 2, 2025 | DEF 14A | Other definitive proxy statements |